ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO0500

Association of Calcium-Channel Blocker Use with Cardiac MRI Parameters in Maintenance HD

Session Information

Category: Dialysis

  • 801 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Lefranc Torres, Armida, Brigham and Women's Hospital, Boston, Massachusetts, United States
  • Chertow, Glenn M., Stanford University, Stanford, California, United States
  • Mc Causland, Finnian R., Brigham and Women's Hospital, Boston, Massachusetts, United States
Background

CCBs are widely used in HD patients, who face high cardiovascular risk. However, their effects on ventricular structure and function are limited.

Methods

In 185 FHN Daily trial participants with baseline and 12-month MRIs, we used linear regression to assess the association between CCB use and changes in cardiac MRI parameters. Models were adjusted for demographics, dialysis parameters, comorbidities, medications, and laboratories

Results

Over 12 months, CCB use (vs. non-use) was associated with a 16 mL (95%CI: 4, 28) increase in LVEDV, an 8 mL (95%CI: 1, 15) increase in LVSV, a 16 mL (95%CI: 2, 31) increase in RVEDV, and a 12 mL (95%CI: 4, 20) increase in RVSV.

Conclusion

CCB use was associated to increased left and right ventricular end-diastolic and stroke volumes over 12 months. Further study is needed to explore the implications for volume status, blood pressure, and clinical outcomes.

OutcomeGroupBaseline12 monthsChange from baseline to 12 monthsUnadjusted differenceAdjusted difference
LVMI (g/m2)No CBB65 ± 2460 ± 23-5 ± 15RefRef
 CCB81 ± 2875 ± 24-5 ± 184 (-1, 8)5 (-0, 10)
LVM (g)No CBB126 ± 49118 ± 47-9 ± 28RefRef
 CCB154 ± 57143 ± 48-11 ± 356 (-3, 14)8 (-2, 17)
LVEDV (mL)No CBB163 ± 51151 ± 4312 ± 38RefRef
 CCB186 ± 59174 ± 51-12 ± 459 (-1, 20)16 (4, 28)
LVESV (mL)No CBB68 ± 3163 ± 27-5 ± 24RefRef
 CCB83 ± 3876 ± 36-7 ± 335 (-3, 12)8 (-1, 17)
LVSV (mL)No CBB95 ± 3088 ± 25-7 ± 27RefRef
 CCB103 ± 3398 ± 28-5 ± 276 (-1, 12)8 (1, 15)
LVEF (%)No CBB59 ± 1159 ± 100 ± 11RefRef
 CCB56 ± 958 ± 101 ± 10-0 (-3, 2)-1 (-5, 2)
RVEDV (mL)No CBB152 ± 53130 ± 47-22 ± 51RefRef
 CCB177 ± 66149 ± 54-28 ± 578 (-5, 21)16 (2, 31)
RVESV (mL)No CBB71 ± 2959 ± 27-12 ± 28RefRef
 CCB82 ± 4468 ± 36-14 ± 424 (-4, 12)6 (-4, 16)
RVSV (mL)No CBB81 ± 3170 ± 27-10 ± 32RefRef
 CCB95 ± 3281 ± 28-13 ± 316 (-2, 13)12 (4, 20)
RVEF (%)No CBB53 ± 954 ± 111 ± 12RefRef
 CCB55 ± 1056 ± 111 ± 121 (-2, 4)1 (-2, 5)

LVMI, left ventricular mass index; LVM, left ventricular mass; LVEDV, left ventricular end-diastolic volume; LVSV, left ventricular end-systolic volume; LVSV, left ventricular stroke volume; LVEF, left ventricular ejection fraction; RVEDV, right ventricular end-diastolic volume; RVSV, right ventricular end-systolic volume; RVSV, right ventricular stroke volume; RVEF, right ventricular ejection fraction.

Digital Object Identifier (DOI)